The authors have no funding, financial relationships, or conflicts of interest to disclose.
Head and Neck
Management of nonesthesioneuroblastoma sinonasal malignancies with neuroendocrine differentiation†
Article first published online: 9 AUG 2012
Copyright © 2012 The American Laryngological, Rhinological, and Otological Society, Inc.
Volume 122, Issue 10, pages 2210–2215, October 2012
How to Cite
Fried, D., Zanation, A. M., Huang, B., Hayes, N., Morris, D. E., Rosenman, J., Varia, M., Funkhouser, W., Weissler, M. and Chera, B. S. (2012), Management of nonesthesioneuroblastoma sinonasal malignancies with neuroendocrine differentiation. The Laryngoscope, 122: 2210–2215. doi: 10.1002/lary.23463
- Issue published online: 20 SEP 2012
- Article first published online: 9 AUG 2012
- Manuscript Accepted: 3 MAY 2012
- Manuscript Revised: 25 APR 2012
- Manuscript Received: 27 MAR 2012
- Neuroendocrine tumors;
- head and neck;
- Level of Evidence: 4
Report the outcomes of patients with nonesthesioneuroblastoma (non-ENB) sinonasal malignancies with neuroendocrine differentiation.
Single Institution Retrospective Case Series.
We conducted a retrospective chart review of 19 biopsy-proven non-ENB sinonasal neuroendocrine carcinomas diagnosed between 1997 and 2010 and treated with multimodality therapy. Kaplan-Meier estimates of local-regional control (LRC), distant metastases–free survival (DMFS), and overall survival (OS) were calculated.
The 3-year LRC, FFDM, and OS rates were 63%, 50%, and 64%, respectively. All nine patients receiving neoadjuvant chemoradiotherapy (CRT) had at least a pathologic partial response: three of seven sinonasal undifferentiated carcinomas and two of two sinonasal neuroendocrine carcinomas had complete pathological responses. All five patients with pathologic complete responses were alive without disease at a median follow-up of 43 (29–67) months.
Having a complete response pathologically to CRT was a favorable prognostic indicator. Neoadjuvant CRT followed by surgery seems to be an efficacious sequence of multimodality therapy.